News: Simtuzumab

We provide the latest news and info on Simtuzumab


Gilead: Pipeline Now Includes Potential Renal Blockbuster (GILD)
Seeking Alpha
Gilead's near term earnings growth will be driven by its domination of the Hepatitis C market. Gilead's drug simtuzumab shows promise as a treatment for liver fibrosis. Gilead's pipeline listing now includes a phase 2 drug to treat diabetic nephropathy.

and more »

Published on Monday 15th of December 2014 02:01:31 PM Read more...


Bidness ETC

Gilead's simtuzumab fails pancreatic cancer trial
PharmaTimes
The company has announced results from a Phase II study evaluating simtuzumab, an inhibitor of the lysyl oxidase-like-2 enzyme, in combination with current standard of care gemcitabine (Eli Lilly's Gemzar). The data show that the addition of simtuzumab ...
Gilead Down on Weak Simtuzumab Data and Sovaldi NewsZacks.com
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously ...Business Wire (press release)
Gilead's simtuzumab fails in Ph II pancreatic cancer studyThe Pharma Letter

all 45 news articles »

Published on Monday 15th of December 2014 02:01:31 PM Read more...


Six Reasons Gilead Sciences Will Head Higher in 2015
Barron's (blog)
... and leadership to increase focus on cancer and immuno-oncology in 2015-16 and may do more bolt-on deals, (6) continued aggressive buybacks and our view is they'll eventually give a dividend in 2016 after seeing out Phase II simtuzumab data H2:15.

Published on Monday 15th of December 2014 02:01:31 PM Read more...


For advanced pancreatic cancer, simtuzumab not significantly more effective ...
Oncology Nurse Advisor
Gilead Sciences, Inc. has announced results from their phase 2 trial studying simtuzumab plus gemcitabine for the treatment of patients with previously untreated advanced pancreatic cancer. Researchers found that patients who received gemcitabine in ...

Published on Monday 15th of December 2014 02:01:31 PM Read more...


Time to Buy This Dip in Gilead Sciences, Inc. Stock?
Motley Fool
Even so, I am doubtful that the market is placing much value in either Simtuzumab or Gilead's superb pipeline in general, given the stock's price-to-earnings ratio of a mere 18. Most of Gilead's peers are currently garnering much higher premiums ...

and more »

Published on Monday 15th of December 2014 02:01:31 PM Read more...


Pulmonary Fibrosis News

Canadian Pulmonary Fibrosis Foundation Lists Current IPF Clinical Trials
Pulmonary Fibrosis News
The study, entitled A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF) (RAINIER), plans to assess simtuzumab as an effective antibody that targets the LOXL2, which participates in the development of ...

Published on Monday 15th of December 2014 02:01:31 PM Read more...


Gilead Sciences, Inc. (NASDAQ:GILD) Again Hits Unexpected Volume Gain With ...
StreetWise Report
The firm's drug simtuzumab shows assure as a treatment for liver fibrosis. The firm pipeline listing now comprises a phase 2 drug to treat diabetic nephropathy. This represents a possible significant market. Therefore, analysts are not only concerned ...

Published on Monday 15th of December 2014 02:01:31 PM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts